MicroRNA (miRNA) 作为一类非蛋白编码 RNA，通过与 3'-非翻译区 (3'-UTR) 碱基配对来转录后调节靶基因的表达。核因子 E2 相关因子 2 (Nrf2) 已被确定为抗氧化防御机制的关键组成部分。失调与癌细胞的化学抗性和放射抗性有关。 miRNA 介导的 Nrf2 信号通路调节已被证明对各种癌症的发展具有重要影响。在本文中，我们回顾了 miRNA 作为 Nrf2 通路调节因子在不同人类癌症中的作用。 Ras 相关结合 (Rab) 蛋白对囊泡运输具有重要的调节作用，并且在预防化疗效果和癌症发展方面具有致癌功能。更重要的是，越来越多的证据表明 miRNA 和 Rab 之间的相互作用已被确定在癌症治疗中发挥关键作用。然而，使用 miRNA 进行治疗应用的重大限制包括 miRNA 的交叉靶向和不稳定性。 miRNA 和 Rab 相互作用的详细情况尚不清楚。在当前的综述中，我们强调了这些分子作为 Nrf2 通路调节因子在癌症发病机制中的作用。还提到了开发 miRNA 作为抗癌疗法的潜在方法和几个障碍。© 2024。作者。

MicroRNAs (miRNAs), as a class of nonprotein-coding RNAs, post-transcriptionally regulate the expression of target genes by base pairing to 3'-untranslated regions (3'-UTRs). Nuclear factor E2-related factor 2 (Nrf2) has been identified as a critical component of the antioxidant defense mechanism. Dysregulation is associated with chemoresistance and radioresistance in cancerous cells. MiRNA-mediated regulation of the Nrf2 signaling pathway has been shown to have important implications for the development of various cancers. In this article, we review the roles of miRNAs as regulators of the Nrf2 pathway in different human cancers. Ras-associated binding (Rab) proteins have an essential role regulation of vesicle transport, as well as oncogenic functions in preventing chemotherapy efficacy and cancer development. More importantly, increased evidence indicated that the interaction between miRNAs and Rabs has been determined to play critical roles in cancer therapy. However, the significant limitations in using miRNAs for therapeutic applications include cross-targeting and instability of miRNAs. The detailed aspect of the interaction of miRNAs and Rabs is not clearly understood. In the current review, we highlighted the involvement of these molecules as regulators of the Nrf2 pathway in cancer pathogenesis. Potential methods and several obstacles in developing miRNAs as an anticancer therapy are also mentioned.© 2024. The Author(s).